Search

Your search keyword '"Van Elssen, Catharina"' showing total 23 results
Start Over Author "Van Elssen, Catharina" Search Limiters Available in Library Collection
23 results on '"Van Elssen, Catharina"'

1. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Author

Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J., Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W., Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J.F.M., Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W.J., Bargetzi, Mario, Klein, Saskia K., Gadisseur, Alain, Westerweel, Peter E., Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A., Hoogendoorn, Mels, Legdeur, Marie-Cecile J.C., Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T., Janssen, Jeroen J.W.M., Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J.M., van Elssen, Catharina H.M.J., Manz, Markus G., Floisand, Yngvar, and Ossenkoppele, Gert J.

Published
2021
Full Text
View/download PDF

2. Low Levels of Serum and Intracellular Vitamin C in Hospitalized COVID-19 Patients

Author

Boerenkamp, Lara S., primary, Gijsbers, Birgit L. M. G., additional, Ververs, Erik-Jan, additional, Pijpers, Eva M. S., additional, Spaetgens, Bart, additional, de Coninck, Aniek, additional, Germeraad, Wilfred T. V., additional, Wodzig, Will K. W. H., additional, Wieten, Lotte, additional, van Gorkom, Gwendolyn N. Y., additional, and van Elssen, Catharina H. M. J., additional

Published
2023
Full Text
View/download PDF

3. P1387: TREATMENT WITH A LEUKEMIA-DERIVED DENDRITIC CELL VACCINE INDUCES INNATE AND ADAPTIVE IMMUNE RESPONSE CORRELATING WITH CLINICAL RESPONSE IN AML PATIENTS IN CR1 WITH MEASURABLE RESIDUAL DISEASE

Author

van Zeeburg, Hester, primary, Kaur Singh, Satwinder, additional, Wagner-Drouet, Eva, additional, Platzbecker, Uwe, additional, Holderried, Tobias, additional, VAN Elssen, Catharina, additional, Giagounidis, Aristoteles, additional, Tore Gjertsen, Bjorn, additional, van de Loosdrecht, Arjan, additional, and Rovers, Jeroen, additional

Published
2023
Full Text
View/download PDF

4. Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Author

Van de Loosdrecht, Arjan A., primary, Cloos, Jacqueline, additional, Wagner-Drouet, Eva-Maria, additional, Platzbecker, Uwe, additional, Holderried, Tobias A.W., additional, van Elssen, Catharina, additional, Giagounidis, Aristoteles, additional, Lehmann, Sören, additional, van Zeeburg, Hester J.T., additional, Rovers, Jeroen, additional, and Gjertsen, Bjorn T., additional

Published
2022
Full Text
View/download PDF

5. Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Author

Van de Loosdrecht, Arjan A., primary, Cloos, Jacqueline, additional, Wagner-Drouet, Eva-Maria, additional, Platzbecker, Uwe, additional, Holderried, Tobias A.W., additional, van Elssen, Catharina, additional, Giagounidis, Aristoteles, additional, Welters, Marij J.P., additional, van der Burg, Sjoerd H., additional, van Zeeburg, Hester J.T., additional, Rovers, Jeroen, additional, and Gjertsen, Bjorn T., additional

Published
2022
Full Text
View/download PDF

6. No Effect of Vitamin C Administration on Neutrophil Recovery in Autologous Stem Cell Transplantation for Myeloma or Lymphoma: A Blinded, Randomized Placebo-Controlled Trial

Author

van Gorkom, Gwendolyn N. Y., primary, Boerenkamp, Lara S., additional, Gijsbers, Birgit L. M. G., additional, van Ojik, Heidi H., additional, Wodzig, Will K. W. H., additional, Wieten, Lotte, additional, Van Elssen, Catharina H. M. J., additional, and Bos, Gerard M. J., additional

Published
2022
Full Text
View/download PDF

7. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis

Author

Tettero, Jesse M., primary, Al-Badri, Waleed K. W., additional, Ngai, Lok Lam, additional, Bachas, Costa, additional, Breems, Dimitri A., additional, van Elssen, Catharina H. M. J., additional, Fischer, Thomas, additional, Gjertsen, Bjorn T., additional, van Gorkom, Gwendolyn N. Y., additional, Gradowska, Patrycja, additional, Greuter, Marjolein J. E., additional, Griskevicius, Laimonas, additional, Juliusson, Gunnar, additional, Maertens, Johan, additional, Manz, Markus G., additional, Pabst, Thomas, additional, Passweg, Jakob, additional, Porkka, Kimmo, additional, Löwenberg, Bob, additional, Ossenkoppele, Gert J., additional, Janssen, Jeroen J. W. M., additional, and Cloos, Jacqueline, additional

Published
2022
Full Text
View/download PDF

8. Increased CD8 T‐cell immunity after COVID‐19 vaccination in lymphoid malignancy patients lacking adequate humoral response: An immune compensation mechanism?

Author

Boerenkamp, Lara S., primary, Pothast, Cilia R., additional, Dijkland, Romy C., additional, van Dijk, Kayleigh, additional, van Gorkom, Gwendolyn N. Y., additional, van Loo, Inge H. M., additional, Wieten, Lotte, additional, Halkes, Constantijn J. M., additional, Heemskerk, Mirjam H. M., additional, and Van Elssen, Catharina H. M. J., additional

Published
2022
Full Text
View/download PDF

13. T cells fail to develop in the human skin-cell explants system; an inconvenient truth

Author

Vanderlocht Joris, Lumeij Stijn BJ, Tonnaer Siebe, van der Stegen Sjoukje JC, Huijskens Mirelle JAJ, Van Elssen Catharina HMJ, Meek Bob, Kirkland Mark A, Hesselink Reinout, Germeraad Wilfred TV, and Bos Gerard MJ

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Haplo-identical hematopoietic stem cell (HSC) transplantation is very successful in eradicating haematological tumours, but the long post-transplant T-lymphopenic phase is responsible for high morbidity and mortality rates. Clark et al. have described a skin-explant system capable of producing host-tolerant donor-HSC derived T-cells. Because this T-cell production platform has the potential to replenish the T-cell levels following transplantation, we set out to validate the skin-explant system. Results Following the published procedures, while using the same commercial components, it was impossible to reproduce the skin-explant conditions required for HSC differentiation towards mature T-cells. The keratinocyte maturation procedure resulted in fragile cells with minimum expression of delta-like ligand (DLL). In most experiments the generated cells failed to adhere to carriers or were quickly outcompeted by fibroblasts. Consequently it was not possible to reproduce cell-culture conditions required for HSC differentiation into functional T-cells. Using cell-lines over-expressing DLL, we showed that the antibodies used by Clark et al. were unable to detect native DLL, but instead stained 7AAD+ cells. Therefore, it is unlikely that the observed T-lineage commitment from HSC is mediated by DLL expressed on keratinocytes. In addition, we did confirm expression of the Notch-ligand Jagged-1 by keratinocytes. Conclusions Currently, and unfortunately, it remains difficult to explain the development or growth of T-cells described by Clark et al., but for the fate of patients suffering from lymphopenia it is essential to both reproduce and understand how these co-cultures really "work". Fortunately, alternative procedures to speed-up T-cell reconstitution are being established and validated and may become available for patients in the near future.

Published
2011
Full Text
View/download PDF

15. Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination

Author

Oth, Tammy, Vanderlocht, Joris, Van Elssen, Catharina H. M. J., Bos, Gerard M. J., and Germeraad, Wilfred T. V.

Subjects
Article Subject
Abstract

A coordinated cellular interplay is of crucial importance in both host defense against pathogens and malignantly transformed cells. The various interactions of Dendritic Cells (DC), Natural Killer (NK) cells, and T helper (Th) cells can be influenced by a variety of pathogen-associated molecular patterns (PAMPs) and will lead to enhanced CD8+ effector T cell responses. Specific Pattern Recognition Receptor (PRR) triggering during maturation enables DC to enhance Th1 as well as NK helper cell responses. This effect is correlated with the amount of IL-12p70 released by DC. Activated NK cells are able to amplify the proinflammatory cytokine profile of DC via the release of IFN-γ. The knowledge on how PAMP recognition can modulate the DC is of importance for the design and definition of appropriate therapeutic cancer vaccines. In this review we will discuss the potential role of specific PAMP-matured DC in optimizing therapeutic DC-based vaccines, as some of these DC are efficiently activating Th1, NK cells, and cytotoxic T cells. Moreover, to optimize these vaccines, also the inhibitory effects of tumor-derived suppressive factors, for example, on the NK-DC crosstalk, should be taken into account. Finally, the suppressive role of the tumor microenvironment in vaccination efficacy and some proposals to overcome this by using combination therapies will be described.

Published
2016
Full Text
View/download PDF

16. Noninvasive Imaging of Human Immune Responses in a Human Xenograft Model of Graft-Versus-Host Disease

Author

Van Elssen, Catharina H.M.J., primary, Rashidian, Mohammad, additional, Vrbanac, Vladimir, additional, Wucherpfennig, Kai W., additional, Habre, Zeina el, additional, Sticht, Jana, additional, Freund, Christian, additional, Jacobsen, Johanne T., additional, Cragnolini, Juanjo, additional, Ingram, Jessica, additional, Plaisier, Loes, additional, Spierings, Eric, additional, Tager, Andrew M., additional, and Ploegh, Hidde L., additional

Published
2017
Full Text
View/download PDF

20. A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer

Author

Brandão, Rita D, primary, Veeck, Jürgen, additional, Van de Vijver, Koen K, additional, Lindsey, Patrick, additional, de Vries, Bart, additional, van Elssen, Catharina HMJ, additional, Blok, Marinus J, additional, Keymeulen, Kristien, additional, Ayoubi, Torik, additional, Smeets, Hubert JM, additional, Tjan-Heijnen, Vivianne C, additional, and Hupperets, Pierre S, additional

Published
2013
Full Text
View/download PDF

23. A randomised controlled phase II trial of preoperative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer.

Author

Brandão, Rita D., Veeck, Jürgen, Van de Vijver, Koen K., Lindsey, Patrick, De Vries, Bart, Van Elssen, Catharina H. M. J., Blok, Marinus J., Keymeulen, Kristien, Ayoubi, Torik, Smeets, Hubert J. M., Tjan-Heijnen, Vivianne C., and Hupperets, Pierre S.

Subjects
CYCLOOXYGENASE 2, RANDOMIZED controlled trials, CELL lines, CANCER cells, BREAST cancer patients, ANTINEOPLASTIC agents, CELECOXIB
Abstract

Introduction: Cyclooxygenase-2 (COX-2) is frequently over-expressed in primary breast cancer. In transgenic breast cancer models, over-expression of COX-2 leads to tumour formation while COX-2 inhibition exerts anti-tumour effects in breast cancer cell lines. To further determine the effect of COX-2 inhibition in primary breast cancer, we aimed to identify transcriptional changes in breast cancer tissues of patients treated with the selective COX-2 inhibitor celecoxib. Methods: In a single-centre double-blind phase II study, thirty-seven breast cancer patients were randomised to receive either pre-operative celecoxib (400 mg) twice daily for two to three weeks (n = 22) or a placebo according to the same schedule (n = 15). Gene expression in fresh-frozen pre-surgical biopsies (before treatment) and surgical excision specimens (after treatment) was profiled by using Affymetrix arrays. Differentially expressed genes and altered pathways were bioinformatically identified. Expression of selected genes was validated by quantitative PCR (qPCR). Immunohistochemical protein expression analyses of the proliferation marker Ki-67, the apoptosis marker cleaved caspase-3 and the neo-angiogenesis marker CD34 served to evaluate biological response. Results: We identified 972 and 586 significantly up- and down-regulated genes, respectively, in celecoxib-treated specimens. Significant expression changes in six out of eight genes could be validated by qPCR. Pathway analyses revealed over-representation of deregulated genes in the networks of proliferation, cell cycle, extracellular matrix biology, and inflammatory immune response. The Ki-67 mean change relative to baseline was -29.1% (P = 0.019) and -8.2% (P = 0.384) in the treatment and control arm, respectively. Between treatment groups, the change in Ki-67 was statistically significant (P = 0.029). Cleaved caspase-3 and CD34 expression were not significantly different between the celecoxib-treated and placebo-treated groups. Conclusions: Short-term COX-2 inhibition by celecoxib induces transcriptional programs supporting anti-tumour activity in primary breast cancer tissue. The impact on proliferation-associated genes is reflected by a reduction of Ki-67 positive cells. Therefore, COX-2 inhibition should be considered as a treatment strategy for further clinical testing in primary breast cancer. Trial registration: ClinicalTrials.gov NCT01695226 [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results